HCPCS code J2786 – Reslizumab injection billing guide

Key takeaways

HCPCS code J2786 bills reslizumab (Cinqair) at 1 mg per unit, so a 210 mg dose is reported as 210 units.

On Medicare claims for single-dose vials, discarded drug goes on a JW line and a no-waste dose takes JZ.

The infusion pairs with CPT 96365 or 96413 depending on payer policy, and an add-on hour applies only past 90 minutes.

Report the J45.5x severity code with J82.83 for eosinophilic asthma, and keep the eosinophil count on file for authorization.

Pabau, practice software with built-in claims management, submits J2786 claims and tracks each one until it is paid or denied.

HCPCS code J2786 bills reslizumab by the milligram

HCPCS code J2786 is the HCPCS Level II code for “Injection, reslizumab, 1 mg.” It covers Cinqair, Teva’s IV anti-IL-5 biologic for adults with severe eosinophilic asthma. One billing unit equals one milligram, so the unit count always matches the dose given.

Medicare covers the drug under Part B because a clinician gives every dose in an office or outpatient setting. Keep these reference facts close when you build the claim.

Weight sets the J2786 unit count

Start with the dose, then convert it. The labeled dose is 3 mg/kg every four weeks, and each milligram is one unit. The math takes four steps.

1. Record the patient’s weight in kilograms on the day of the infusion.
2. Multiply the weight by 3 to get the dose in milligrams. A 70 kg patient needs 210 mg.
3. Round the dose to the nearest whole milligram. That figure is your J2786 unit count.
4. Count the 100 mg vials opened, then subtract the dose to find any discarded drug.

The weight on the claim must match the infusion note and the pharmacy preparation record. If the three disagree, an auditor can question the whole dose.

The CPT infusion code goes on its own claim line

Reslizumab is an IV infusion, so every J2786 line needs a CPT drug administration code beside it. The drug and its administration are separate line items, and each is paid on its own.

The right initial code depends on CPT rules and payer policy. Many payers want 96365 for a non-cancer biologic like reslizumab. CPT also lets 96413 cover some monoclonal antibodies, so read the plan’s policy first.

Timing rarely causes trouble here. Reslizumab runs 20 to 50 minutes, so most visits bill one initial code and nothing more. Under CPT time rules, an add-on hour such as 96415 counts only from 91 minutes, which is 31 minutes past the first hour. Record start and stop times on every visit anyway.

J2786 diagnosis codes must show severity and phenotype

Every J2786 claim needs an ICD-10-CM code that supports medical necessity. Payers look for severe asthma and an eosinophilic phenotype, and those facts live in two different codes.

The J45.5x codes describe severity, and they say nothing about the eosinophilic phenotype. J82.83 carries the phenotype, and its tabular note tells you to code the J45 severity code first. Report both, and keep the eosinophil count on file to back them up.

Prior authorization usually comes before the first J2786 infusion

Most commercial plans and many Medicare Advantage plans require prior authorization for J2786. Original Medicare does not, though its contractors still review medical necessity. Billing a plan that requires approval without a number is a fast route to a CO-197 denial.

Criteria vary by plan, but most requests ask for the same five items:

• Eosinophil count: Many plans want at least 400 cells/µL, measured within the past 12 months. Each plan sets its own threshold.
• Step therapy: Show that the patient failed, or cannot take, inhaled corticosteroids plus another controller, such as a long-acting beta-agonist.
• Prescriber specialty: Some plans approve J2786 only for pulmonologists or allergists, so check before the request goes in.
• Diagnosis: Reference the J45.5x severity code with J82.83, plus the clinical notes behind them.
• Authorization number: Once approved, it goes in box 23 of the CMS-1500 or the REF*G1 segment of the 837P. A missing number triggers CO-197 even when approval exists.

NDC reporting for J2786 counts milliliters, not milligrams

Medicaid requires an NDC on physician-administered drug claims, and many commercial plans do too. Use the 11-digit NDC in 5-4-2 format, matched to the vial you opened.

Cinqair packaging can change, so confirm current NDCs in the AAPC Codify HCPCS lookup or the CMS NDC-HCPCS crosswalk. Each Medicaid claim needs three NDC fields:

• The 11-digit NDC from the vial label.
• The NDC quantity in the NDC unit of measure. Cinqair is 10 mg/mL, so a 210 mg dose is 21 mL.
• The unit qualifier, such as ML, UN, GR or F2, per your state Medicaid rules.

A frequent slip is entering 210 as the NDC quantity. The HCPCS line counts milligrams, while the NDC line counts milliliters.

JW and JZ modifiers tell Medicare what happened to the vial

On Medicare claims, J2786 from a single-dose vial needs JW or JZ. JW reports discarded drug, and JZ confirms none was discarded. CMS has enforced the JZ requirement since July 1, 2023.

The discarded amount goes on its own claim line. For example, a 210 mg dose drawn from three vials leaves 90 mg, billed as 90 units of J2786-JW.

The most common modifier error is leaving both off. Medicare contractors can return or deny those lines. Medicaid and commercial plans set their own rules, so check them before adding JW or JZ.

How Medicare pays for J2786

Medicare pays J2786 under Part B at the average sales price plus 6%, under Section 1847A of the Social Security Act. CMS updates the rate each quarter, so check the CMS ASP pricing files before quoting an expected payment.

Place of service changes the payment system and the claim form. It does not, by itself, lower the drug rate. Hospital outpatient departments bill under OPPS, which generally pays separately payable drugs at ASP plus 6% too.

Part B coverage rules shape every J2786 claim

Physician-administered drugs fall under Part B, not Part D. Reslizumab qualifies because a clinician gives it in a covered setting. Part D covers self-administered drugs from a pharmacy, so it does not pay for a reslizumab infusion.

• Direct supervision: A physician or non-physician practitioner must be in the office suite during the infusion. They need not be in the room, but must be immediately available.
• Incident-to billing: A nurse can give the infusion under physician supervision and bill it incident-to. The physician needs an active treatment plan in the record.
• MAC policy variation: Medicare Administrative Contractors may publish coverage articles with extra criteria for anti-IL-5 biologics. Check your MAC’s site, such as Noridian, Novitas or Palmetto, before the first claim.
• Commercial payers: Coverage criteria for J2786 vary widely across plans. Read each plan’s drug policy rather than assuming Part B rules carry over.

A J2786 claim moves through five hands before payment

Each J2786 claim follows the same path through your revenue cycle management process. Most denials start at one of these five steps.

1. Authorization: The front desk confirms the plan, checks eligibility and logs the approval number.
2. Infusion: The nurse records weight, dose, vials, lot, NDC and start and stop times.
3. Coding: The biller enters the J2786 units, any JW line, the CPT code and both diagnosis codes.
4. Submission: The claim goes out on the 837P with the NDC fields and the authorization number.
5. Remittance: The 835 posts the payment or a denial code. Denied lines get corrected and resubmitted.

Documentation that holds up in a J2786 audit

Auditors reviewing a J2786 claim look for six items in the record. If one is missing, they can flag the claim as unsupported.

• Eosinophil count and date: The blood eosinophil count in cells/µL, measured within 12 months of the infusion, with the lab date.
• Dose calculation: Weight in kilograms on the date of service, the calculated dose, and confirmation that the amount given matches it.
• Infusion start and stop times: When the IV began and ended, showing the 20 to 50 minute window from the label.
• Lot number, NDC and waste: The vial lot and NDC, plus any discarded amount and the reason. A witness signature on the waste log is recommended.
• Response assessment: Asthma control, any exacerbations since the last dose, and the case for continuing reslizumab.
• Authorization number: The payer-issued number, matching what goes in box 23 or the 837P.

A clean claim for J2786 carries all six before it leaves the practice. Building them into the infusion note template means staff capture them during the visit, while the details are fresh.

Common J2786 denials and how to fix them

J2786 denials cluster around four failure points. They are missing modifiers, missing authorization, unsupported diagnoses and NDC errors. Tracking which one hits most often sharpens your denial management work.

For every CARC and RARC you may see on an 835 remittance, keep the medical billing denial codes reference handy.

Before you submit a J2786 claim, run this checklist

Two minutes here can save a resubmission later. Check each item against the infusion record:

• Units equal the milligrams given, not the vials or milliliters.
• A JW line covers any discarded drug, or JZ confirms none.
• The CPT administration code fits payer policy and the recorded times.
• J45.5x and J82.83 both appear, with the eosinophil count on file.
• The authorization number sits in box 23 or REF*G1.
• The NDC has 11 digits, with the quantity in milliliters.
• The infusion note says IV, not subcutaneous.

Asthma biologic codes often confused with J2786

Several asthma biologics have their own codes. Billing the wrong one misstates the drug given, which turns a simple denial into a compliance problem.

J2786 is the only IV infusion in this group, while J0517 and J2182 are subcutaneous injections. Dupilumab has no dedicated J-code, so payers that cover it in the office ask for J3590 with the drug name and NDC. If a J2786 claim comes from a setting with no IV capability, the code is likely wrong.

How Pabau keeps J2786 claims moving

Most J2786 errors happen when details are retyped between the infusion note and the claim. Weight, units and NDC pass through several hands before submission.

Pabau’s claims software for practices fills the CMS-1500 from the patient record. The J2786 code attached to the service lands on the charge line, and recorded diagnoses seed the ICD-10 fields. The claim cannot be sent until its required fields are complete.

In the US, claims go out through Claim.MD with real-time eligibility checks. Pabau then tracks each claim’s status and posts the remittance when payment or a denial comes back.

Send cleaner J2786 claims with Pabau

Pabau’s claims management fills claims from the patient record, checks required fields before sending, and tracks every reslizumab claim from submission to payment.

Book a demo

Conclusion

Reslizumab billing is a math problem before it is a coding problem. Get the weight, dose and vial count right in the infusion note, and the units, JW line and NDC quantity follow.

The weak points sit outside the drug code itself. Authorization numbers go missing, J82.83 gets left off, and the NDC quantity lands in milligrams. Build those three checks into your routine, and most J2786 denials stop before submission.

Software helps once the numbers are right. Pabau, the practice management platform we build, fills the claim from the record and tracks it to payment. Book a demo to see how it handles your infusion billing.

Continue your research

Need a full overview of how medical billing works? Medical billing compliance covers the regulatory framework and documentation standards that apply to physician-administered drug claims.

Want to understand 837P claim structure for J-code submissions? Superbill guide explains how the superbill maps to the 837P and CMS-1500 fields billers populate for drug codes.

Looking for best-practice claims submission workflows? Best medical billing software for US practices reviews platforms that support J-code, modifier, and NDC field requirements.

Frequently asked questions about HCPCS code J2786